Highlights
- In a Phase 1 therapeutic non-small cell lung cancer (NSCLC) trial, the first patient has been dosed.
- The first patient was dosed at the Wollongong Hospital, New South Wales.
- The first-in-human trial aims to evaluate the safety and tolerability of 177Lu-RAD 204 in individuals diagnosed with NSCLC and tested positive for PD-L1.
Radiopharm Theranostics Limited (ASX: RAD) has achieved a significant milestone in its efforts to develop transformative oncology radiotherapeutics. The company successfully administered the first therapeutic dose in the Phase 1 trial of RAD 204, a proprietary nanobody targeting PD-L1 (programmed death-ligand 1), which is commonly expressed in NSCLC.
The first patient was dosed at Wollongong Hospital in New South Wales. This important study is being conducted across several sites in Australia, including Hollywood Private Hospital in Western Australia, Princess Alexandra Hospital in Queensland, and Wollongong Hospital.
RAD shares were trading 2.86% higher at AUD 0.036 apiece at the time of writing on 10 July 2024.
